The tweet was deleted by the author.
But we saved everything 🙂.
Caribou Biosciences has released its financial results for the second quarter of 2026, accompanied by a comprehensive update on its ongoing business operations.
The company, active in the gene editing and cell therapy space, is highlighting its progress and outlook for the remainder of the year. Investors and analysts are encouraged to review the detailed earnings report for insights into Caribou Biosciences financial performance and strategic developments.
View post on X Loading...
Earlier this year, Caribou Biosciences announced that its ANTLER abstract was accepted as an e-poster for PPLC 2026. The presentation featured data on the company's vispa-cel program. These developments provide context for Caribou's ongoing updates on its research and clinical initiatives.